Back to results
US 9,809,648 B2Granted
Engineered anti-IL-23p19 antibodies
AssigneeMerck Sharp & Dohme Corp.
InventorsLeonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
Life of this patent
Estimating the term…
Abstract
Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
Claims12
A monoclonal antibody or antigen binding fragment thereof, that binds to human IL-23 at an epitope comprising residues 20-30 and 82-110 of SEQ ID NO:
- 47, wherein the antibody or antigen binding fragment thereof comprises:
- a) a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
- i) CDRL1 comprises the sequence of SEQ ID NO:
- 36;
- ii) CDRL2 comprises the sequence of SEQ ID NO:
- 41;
- and
- iii) CDRL3 comprises the sequence of SEQ ID NO:
- 46;
- and
- b) a heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein:
- i) CDRH1 comprises the sequence of SEQ ID NO:
- 19;
- ii) CDRH2 comprises a sequence selected from the group consisting of SEQ ID NOs:
- 24-26;
- and
- iii) CDRH3 comprises the sequence of SEQ ID NO:
- 31.
15 more elements
Dependencies are inferred from the claim text.